FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.5711
Abstract: Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus nephritis (LN) did not confirm benefit;Arthritis Rheum 201264:1215 and 2013;65:2368). Objectives One possible explanation for this failure stems from the fact that B… read more here.
Keywords: group; anti baff; baff; anti cd20 ... See more keywords